



PHARMAZZ  
SAVING LIVES THROUGH INNOVATION

PHARMAZZ INDIA PRIVATE LIMITED  
(Subsidiary of Pharmazz, Inc. USA)  
CIN No. : U24100DL2011FTC215954

H-6, Site-C, Surajpur Industrial  
Area, Greater Noida (UP) -  
201307, INDIA

☎ : +91 (120)256-9779  
✉ : info@pharmazz.com  
🌐 : www.pharmazz.com

Date: July 18, 2022

This is to certify that, Pharmazz India Pvt. Ltd., has conducted following Non-Clinical Toxicity studies on Centhaquine citrate (PMZ-2010) at Vanta Bioscience Limited, Chennai for submission of IND to CDSCO and US FDA for permission to undertake phase III clinical trial.

M/s Pharmazz secured the US FDA consent to initiate Phase III clinical trial of Centhaquine in patients with hypovolemic shock.

The list of studies conducted at Vanta Bioscience Limited are:

- 17T003-G: Study on the effects of Centhaquine citrate (PMZ-2010) on Male fertility in Sprague Dawley rats.
- 18-206-G: 28 days Repeated dose Toxicity Study of Centhaquine Citrate (PMZ-2010) by Intravenous Injection Route in Sprague Dawley Rats.
- 18-317-G: Effect of Centhaquine Citrate (PMZ-2010) on Fertility and Early Embryonic Developmental to Implantation (Segment-I) in Sprague Dawley Rats.
- 18-318-G: Embryo-fetal Developmental Toxicity (Segment-II) Study of Centhaquine Citrate (PMZ-2010) in Sprague Dawley Rats.
- 18-319-G: Embryo-fetal Developmental Toxicity (Segment-II) Study of Centhaquine Citrate (PMZ-2010) in New Zealand White Rabbits.

Thanking you,  
Yours faithfully,



Dr. Manish S. Lavhale  
Managing Director